There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 1 | 1 | 2498.8 |
| 1 | 11 | 2498.7 |
| 1 | 29 | 2498.6 |
| 1 | 12 | 2498.5 |
| 1 | 14 | 2498.4 |
| Ask | Qty | Orders |
|---|---|---|
| 2498.9 | 5 | 24 |
| 2499.4 | 1 | 1 |
| 2499.5 | 3 | 23 |
| 2499.6 | 3 | 29 |
| 2499.8 | 1 | 10 |
Annual Revenue,rose 23.92%, in the last year to ₹28,382.48 Cr. Its sector's average revenue growth for the last fiscal year was 12.14%.Annual Net Profit,rose 62.51% in the last year to ₹5,332.84 Cr. Its sector's average net profit growth for the last fiscal year was 2.16%.Price to Earning Ratio,is 20.95, lower than its sector PE ratio of 43.36.
Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin Limited is a Mumbai‑headquartered, innovation‑led transnational pharmaceutical company. Incorporated in 1983, the company develops, manufactures and markets a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) . Lupin has significant presence across Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro‑Intestinal, Anti‑Infectives and Nonsteroidal Anti‑Inflammatory Drug therapies, and is a global leader in Anti‑TB and Cephalosporins . Its products are distributed in over 100 markets, with strong presence across North America, EMEA, LATAM, APAC and India; operations span 112 countries as per the Business Responsibility and Sustainability Report . Manufacturing locations are spread across India, USA, Mexico and Brazil, with 15 manufacturing sites and seven research centres supporting global supply and innovation fileciteturn5 .
As on March 31, 2025, Lupin had 32 subsidiaries worldwide (do not list names) and one joint venture, reflecting its diversified operating footprint and corporate structure . Key milestones in the latest year included 41 product filings, 52 approvals and 87 patents secured, underscoring the company’s focus on complex generics and specialty portfolios across major markets .
– North America contributed 36 Per cent to revenues in FY25, affirming Lupin’s scale in the U.S. generics market .
– India contributed 34 Per cent to global turnover in FY25 .
– Other Developed Markets (Europe and Australia) contributed 11 Per cent of global revenues .
– Emerging Markets contributed 11 Per cent of global revenues .
– Domestic vs. International: On a standalone basis, exports comprised 53.9 Per cent of total sales in FY25 .
– Manju D. Gupta – Chairperson
– Vinita Gupta – Chief Executive Officer
– Nilesh D. Gupta – Managing Director
– Ramesh Swaminathan – Executive Director, Global CFO, Head of IT and API Plus SBU
– Amit Kumar Gupta – Company Secretary
– Portfolio and market expansion: Lupin acquired Eli Lilly’s Huminsulin and three diabetes products from Boehringer Ingelheim in India; it also acquired two specialty brands from Sanofi (Aarane in Germany and Nalcrom in Canada and the Netherlands) .
– Biologics progress: The company launched its first biosimilar, Rymti, in Canada and filed for Ranibizumab in the EU .
– Subsidiary additions: Lupin incorporated Lupin Lanka (Private) Limited in Sri Lanka and Lupin NZ Limited in New Zealand, expanding its presence in South Asia and Oceania .
– Pipeline momentum: In FY25, Lupin filed 41 products and received 52 approvals; 87 patents were secured, highlighting continued R&D intensity across inhalation, injectables, ophthalmic and oral segments .
– Regional performance highlights: North America sales grew 15.9 Per cent; Other Developed Markets rose 23.4 Per cent; Emerging Markets increased 6.8 Per cent, supported by differentiated portfolios and supply chain agility .
Lupin Limited has delivered a 105.89% absolute return over the past 5 years, equivalent to a CAGR of 15.54% per annum. The stock was priced at ₹1,186.65 in Jul 2021 and has risen to ₹2,443.20 as of 18 Jul 2026. An investment of ₹1,00,000 in Lupin Limited five years ago would be worth ₹2,05,890.00 today.
For Q4 FY26, Lupin Limited reported: Revenue (Net Sales): ₹52346.00 Cr - Up 16.29% year-on-year from ₹45011.90 Cr in Q3 FY26. Net Income (PAT): ₹21636.90 Cr - Up 201.58% year-on-year from ₹7174.50 Cr in Q3 FY26.
Lupin Limited has delivered a return of 4.92% over the last 3 months. The stock was trading at ₹2,326.10 on 17 Apr 2026 and is currently at ₹2,443.20 as of 18 Jul 2026, reflecting a Gain of ₹117.10 per share over this period.
The intraday high for Lupin Limited on the NSE today (18 Jul 2026) was ₹2,529.50. This compares to the 52-week high of ₹2,529.50 recorded on 16 Jul 2026. Today's high was 0.00% above the 52-week high.
Lupin Limited has delivered 26.45% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,529.50 on 16 Jul 2026 and a 52-week low of ₹1,836.80 on 06 Aug 2025. It is currently trading at ₹2,443.20 as of 18 Jul 2026.
As of 18 Jul 2026, the share price of Lupin Limited is ₹2,443.20 on the NSE and ₹2,441.50 on the BSE. The stock opened at ₹2,506.00, touched a high of ₹2,529.50 and a low of ₹2,428.00 during today's session.
Over the last 6 months, Lupin Limited has given a return of 12.22%. The stock was priced at ₹2,177.10 on 19 Jan 2026 and has Rise to ₹2,443.20 as of 18 Jul 2026, a change of ₹266.10 per share.
The intraday low for Lupin Limited on the NSE today was ₹2,428.00. The stock's 52-week low stands at ₹1,836.80, recorded on 06 Aug 2025. Today's low is 32.19% above the 52-week low, indicating the stock is trading well above its yearly lows.
The all-time high (ATH) for Lupin Limited was ₹2,503.30, recorded on 09 Jul 2026. At the current price of ₹2,443.20, the stock is trading 2.40% below its all-time high. The all-time low recorded was ₹278.53 on 14 Jan 2010.
Yes,Lupin Limited has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 46.00 per share between FY2022 and FY2026, with the most recent dividend of ₹18.00 per share for May 26, with an ex-dividend date of 17 Jul 2026. At the current market price of ₹2,443.20, the trailing dividend yield of Lupin Limited stands at 30.00%.
